Discordant PSMA / FDG Disease

Quick Answer

In advanced prostate cancer, PSMA and FDG report on different biology: PSMA on the prostate-lineage cell-surface target, FDG on glycolytic tumour burden. Most lesions are PSMA-avid, but a subset — typically dedifferentiated, aggressive, or neuroendocrine-transformed disease — becomes PSMA-low/negative while turning FDG-positive. These discordant lesions matter enormously for theranostics: a patient with significant PSMA-negative/FDG-positive disease is a poor candidate for PSMA radioligand therapy, because the very lesions driving the disease will not bind the therapeutic ligand.

Why the two tracers diverge

PSMA expression is a marker of preserved prostate epithelial differentiation; FDG avidity tracks glycolytic, proliferative burden. As prostate cancer dedifferentiates — losing androgen-receptor and prostate-lineage programmes, sometimes transforming toward a neuroendocrine/small-cell phenotype — PSMA expression falls while glucose metabolism rises. The result is a lesion that is bright on FDG but dim or absent on PSMA: the imaging signature of aggressive, treatment-resistant biology.

The four combinations

Thinking in a 2×2 of PSMA (±) and FDG (±) organises the whole problem:

• PSMA+ / FDG− or PSMA+ / FDG+ — PSMA-expressing disease; the target is present, and PSMA radioligand therapy can reach it.
• PSMA− / FDG+ — the discordant, high-risk phenotype: dedifferentiated or neuroendocrine disease that PSMA therapy will miss.
• PSMA− / FDG− — indolent or low-volume disease below detection, or non-viable/treated tissue, interpreted in context.

The clinically decisive cell is PSMA−/FDG+: its volume and distribution determine whether PSMA-directed therapy is appropriate.

Why it drives theranostic selection

PSMA radioligand therapy (e.g. ¹⁷⁷Lu-PSMA-617) delivers radiation only to cells that bind the PSMA ligand. If a meaningful fraction of a patient's tumour burden is PSMA-negative but metabolically active on FDG, that disease is untreated by the radioligand and will progress even if the PSMA-avid lesions respond. Dual-tracer assessment (PSMA plus FDG) is therefore used in many programmes to screen out patients with substantial discordant disease, and to explain the pattern of a mixed or early response. The corollary: a PSMA PET that "looks better than the patient" should prompt consideration of occult FDG-positive, PSMA-negative disease.

The concept generalises beyond prostate. Any theranostic pair — SSTR imaging before DOTATATE therapy, for example — carries the same logic: the therapy can only treat what expresses the target, and a second tracer (often FDG) that lights up target-negative, aggressive disease is the standard way to detect the mismatch. In neuroendocrine tumours this is formalised as the concept of flip-flop between high SSTR/low FDG (favourable) and low SSTR/high FDG (aggressive) biology.

Pitfalls

• Do not equate PSMA-avidity with disease extent. A "clean" PSMA scan does not exclude FDG-positive, PSMA-negative burden.
• Physiologic and benign PSMA uptake (salivary/lacrimal glands, kidneys, bowel, celiac ganglion, healing bone) must not be mistaken for target-positive tumour when judging eligibility.
• Timing and treatment effects alter both tracers; interpret discordance against recent systemic therapy.

Clinical response

When discordant disease is suspected — rising markers with a disproportionately low PSMA burden, rapid clinical progression, or histologic dedifferentiation — dual-tracer imaging clarifies theranostic eligibility and prognosis. Substantial PSMA-negative/FDG-positive disease argues against PSMA radioligand therapy alone and toward alternative or combination systemic strategies.

Self-Check

Key References

• Studies of dual PSMA/FDG PET for selection and prognostication in mCRPC (e.g. dual-tracer eligibility analyses preceding ¹⁷⁷Lu-PSMA therapy).
• Reviews of neuroendocrine tumour SSTR/FDG "flip-flop" and target-negative disease in theranostics.